Highlights
The ELAN-RT trial established that hypofractionated split-course radiotherapy (HSC-RT) is non-inferior to standard fractionated radiotherapy (SF-RT) regarding locoregional response at six months in frail patients aged 70 and older.
HSC-RT significantly reduced the treatment burden, requiring only 20 fractions compared to the 35 fractions necessitated by the standard protocol.
